Xbrane Sets Cash Target Ahead Of Lucentis Ambitions In 2022
Swedish Firm Names New Strategic Targets
Swedish developer Xbrane Biopharma has identified a timeline to turn its cash flows positive, with plans to roll-out biosimilar Lucentis next year.
You may also be interested in...
Xbrane Biopharma has celebrated after being granted two Swedish patents covering its “high-yield” protein expression platform that the biosimilars specialist expects to act as the basis for international applications.
Xbrane Biopharma has taken a key step on its journey to begin generating cash from operations by early 2024 at the latest, after its Xlucane biosimilar ranibizumab asset was submitted to the European Medicines Agency by co-development and commercialization partner Stada.
With ambitions to file biosimilar ranibizumab and initiate one new development program per year, Sweden’s Xbrane Biopharma has brought in millions of much needed fresh capital to fuel operations.